MediPharm Labs Corp (TSXV: LABS)(CVE: LABS)

Established in 2015, MediPharm Labs Corp (TSXV: LABS) has quickly emerged as a leader in the development of private label cannabis oil and concentrates.   Through its proprietary technology, MediPharm Labs Corp, and its wholly-owned subsidiary MediPharm Labs, Inc. (collectively known as “MediPharm” or “Company”), specializing in the extraction, formulation, and processing of pharmaceutical grade cannabis oil.

MediPharm is a great company with the vision to invest heavily in the development of its proprietary methodologies, facilities, and expertise to deliver safe and measurable doses of cannabis oil.  With its newly constructed, state-of-the-art 70,000 square foot production facility located in Barrie, Canada, MediPharmhas strategically positioned itself to capitalize on the trend toward the production of cannabis-derived oil, instead of focusing solely on dry flower processing.   With oil and concentrates perceived as the healthier alternative to dry flower, MediPharm is one of the first in the cannabis market to meet this increasing demand.   Its current extraction capacity of 150,000 kg of the dry flower is expected to grow to 250,000 kg by the middle of 2019.

This vision has paid off.  MediPharm’s increasing production and focus on product quality had attracted the attention of Licensed Producers in the industry.  On February 12, 2019, MediPharm signed its fourth private label agreement to supply $35 million of its oils and concentrates, bringing the collective value of its private label agreements to $85 million over the next 15 months.

In addition to its focus on product quality and purity, MediPharm achieved a first-mover advantage in Canada as it was the first company to achieve the status of the licensed producer of cannabis oil through the Access to Cannabis for Medical Purposes Regulations (ACMPR) without first being a licensed cultivator.  The Company was also recognized as the “start-up of the year” award in the Canadian Cannabis Award ceremony.

MediPharm’s continued investment in infrastructure, research and development, and expertise have solidified its position as a dominant player in the cannabis-oil and concentrate market.  With an anticipated completion date in 2019, the Company is currently constructing an extraction and production facility in Australia.  Not only will this increase their volume of production, but the completed facility will also strategically place them in a position to better serve the international market.  Planned retail outlets in Manitoba are expected to open in 2019.  With the Company’s continued investment in its expertise and production capacities in this skyrocketing market, MediPharm Labs Corp is a great stock to invest in for the future.


Related Posts :